Joseph E Levitt, MD
Critical Care (Intensivists) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Levitt’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A87822 · Current
Licensed to practise in California · since 2004 · expires 2028-04-30 · University of Minnesota Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$65,758
Medicare paid this office $65,758 for 317 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 80 | $32,150 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $9,895 | $104 |
| Return visit (30+ min) | 54 | $5,575 | $86 |
| Long return visit (40+ min) | 26 | $4,249 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,578 | $156 |
See all 12 services
| Critical care, first 30-74 minutes | 80 | $32,150 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $9,895 | $104 |
| Return visit (30+ min) | 54 | $5,575 | $86 |
| Long return visit (40+ min) | 26 | $4,249 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,578 | $156 |
| New patient visit (60+ min) | 14 | $2,120 | $151 |
| Return visit (30+ min) | 11 | $1,112 | $101 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $539 | $49 |
| Test to examine how well the lungs exchange gases | 54 | $439 | $8 |
| Test to measure expiratory airflow and volume | 44 | $334 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 32 | $290 | $9 |
| Test to determine lung volumes using sensors | 22 | $233 | $11 |
Who their Medicare patients are
317 Original Medicare patients in 2024. Average age 73 · Under 65 11% · 85 and older 12% · Women 52% · Also on Medicaid 30% · Health risk score 2.46. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · COPD 43% · Coronary heart disease 39% · Atrial fibrillation 37% · Chronic kidney disease 35% · Heart failure 34% · Diabetes 33% · Depression 26% · Cancer 21% · Stroke 20% · Dementia 14%.
The office billed $496,002, Medicare allowed $85,665 and paid $65,758; for 643 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 317 | 643 | 73 | 2.46 | $496,002 | $65,758 |
| 2023 | 326 | 684 | 73 | 2.53 | $493,857 | $68,178 |
| 2022 | 294 | 670 | 73 | 2.49 | $498,310 | $63,877 |
| 2021 | 228 | 463 | 73 | 1.94 | $220,096 | $34,313 |
| 2020 | 151 | 321 | 72 | 2.78 | $271,844 | $38,760 |
| 2019 | 484 | 1,048 | 73 | 2.29 | $429,649 | $78,094 |
| 2018 | 443 | 968 | 72 | 2.37 | $417,302 | $69,625 |
| 2017 | 367 | 799 | 72 | 2.17 | $344,908 | $57,999 |
| 2016 | 362 | 764 | 72 | 2.34 | $333,613 | $57,643 |
| 2015 | 255 | 521 | 70 | 2.14 | $333,870 | $57,145 |
| 2014 | 168 | 344 | 71 | 2.51 | $250,675 | $44,714 |
| 2013 | 178 | 346 | 70 | 2.46 | $218,362 | $41,444 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Critical care, first 30-74 minutes | 81 | $36,307 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $9,873 | $110 |
| Return visit (30+ min) | 53 | $5,223 | $84 |
| Long return visit (40+ min) | 23 | $3,653 | $126 |
| New patient visit (60+ min) | 16 | $2,672 | $167 |
| New patient visit (45+ min) | 17 | $2,075 | $122 |
| Test to examine how well the lungs exchange gases | 76 | $530 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 42 | $349 | $8 |
| Test to measure expiratory airflow and volume | 52 | $327 | $6 |
| Test to determine lung volumes using sensors | 32 | $309 | $9 |
2022: 9 services
| Critical care, first 30-74 minutes | 65 | $39,562 | $189 |
| Long return visit (40+ min) | 32 | $5,225 | $127 |
| Return visit (30+ min) | 53 | $4,692 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,574 | $93 |
| New patient visit (60+ min) | 13 | $2,191 | $169 |
| Test to examine how well the lungs exchange gases | 89 | $722 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 59 | $550 | $9 |
| Test to determine lung volumes using sensors | 44 | $477 | $11 |
| Test to measure expiratory airflow and volume | 48 | $357 | $7 |
2021: 9 services
| Critical care, first 30-74 minutes | 29 | $16,544 | $199 |
| Long return visit (40+ min) | 31 | $4,921 | $129 |
| Return visit (30+ min) | 26 | $2,485 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,291 | $95 |
| New patient visit (60+ min) | 12 | $2,235 | $186 |
| Test to examine how well the lungs exchange gases | 84 | $600 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 51 | $434 | $9 |
| Test to determine lung volumes using sensors | 44 | $429 | $10 |
| Test to measure expiratory airflow and volume | 63 | $424 | $7 |
2020: 6 services
| Critical care, first 30-74 minutes | 41 | $27,618 | $200 |
| Return visit (30+ min) | 40 | $2,605 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,839 | $97 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,316 | $73 |
| Test to examine how well the lungs exchange gases | 21 | $122 | $6 |
| Test to measure expiratory airflow and volume | 17 | $90 | $5 |
2019: 14 services
| Critical care, first 30-74 minutes | 64 | $30,698 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 100 | $16,997 | $94 |
| Return visit (30+ min) | 69 | $5,751 | $68 |
| Long return visit (40+ min) | 37 | $4,745 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,455 | $124 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 14 | $1,846 | $123 |
| New patient visit (60+ min) | 12 | $1,828 | $152 |
| New patient visit (45+ min) | 16 | $1,801 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $1,782 | $66 |
| Test to examine how well the lungs exchange gases | 137 | $1,147 | $8 |
| Test to measure expiratory airflow and volume | 141 | $1,124 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 76 | $912 | $12 |
| Test to determine lung volumes using sensors | 55 | $621 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $166 | $11 |
2018: 14 services
| Critical care, first 30-74 minutes | 62 | $31,278 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $9,987 | $93 |
| Return visit (30+ min) | 86 | $7,347 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,123 | $179 |
| Long return visit (40+ min) | 24 | $2,793 | $90 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,444 | $122 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 15 | $1,855 | $109 |
| New patient visit (45+ min) | 17 | $1,769 | $104 |
| Test to examine how well the lungs exchange gases | 137 | $1,137 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 84 | $979 | $12 |
| Test to measure expiratory airflow and volume | 88 | $660 | $7 |
| Test to determine lung volumes using sensors | 60 | $655 | $11 |
| Test to measure expiratory airflow and volume | 40 | $288 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | $199 | $11 |
2017: 11 services
| Critical care, first 30-74 minutes | 53 | $28,067 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $6,731 | $93 |
| Return visit (30+ min) | 71 | $5,892 | $65 |
| Long return visit (40+ min) | 25 | $2,980 | $93 |
| New patient visit (45+ min) | 27 | $2,798 | $104 |
| New patient visit (60+ min) | 18 | $2,476 | $138 |
| Test to examine how well the lungs exchange gases | 126 | $940 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 55 | $589 | $11 |
| Test to measure expiratory airflow and volume | 88 | $585 | $6 |
| Test to determine lung volumes using sensors | 40 | $389 | $10 |
| Test to measure expiratory airflow and volume | 29 | $205 | $6 |
2016: 14 services
| Critical care, first 30-74 minutes | 44 | $24,851 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $6,936 | $92 |
| Return visit (30+ min) | 54 | $4,624 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,245 | $180 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $2,946 | $113 |
| New patient visit (45+ min) | 24 | $2,768 | $115 |
| Long return visit (40+ min) | 19 | $2,378 | $99 |
| New patient visit (60+ min) | 14 | $2,096 | $150 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,160 | $89 |
| Test to examine how well the lungs exchange gases | 117 | $928 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 68 | $796 | $12 |
| Test to measure expiratory airflow and volume | 74 | $535 | $7 |
| Test to determine lung volumes using sensors | 45 | $494 | $11 |
| Test to measure expiratory airflow and volume | 18 | $129 | $7 |
2015: 9 services
| Critical care, first 30-74 minutes | 68 | $30,186 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $7,446 | $93 |
| Return visit (30+ min) | 61 | $5,313 | $66 |
| New patient visit (45+ min) | 27 | $3,028 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,896 | $181 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $1,213 | $110 |
| Test to examine how well the lungs exchange gases | 34 | $279 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $212 | $12 |
| Test to measure expiratory airflow and volume | 27 | $205 | $8 |
2014: 5 services
| Critical care, first 30-74 minutes | 58 | $25,607 | $195 |
| Return visit (30+ min) | 44 | $4,246 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $3,327 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,979 | $180 |
| New patient visit (45+ min) | 13 | $1,503 | $116 |
2013: 5 services
| Critical care, first 30-74 minutes | 54 | $20,607 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $7,294 | $90 |
| Return visit (30+ min) | 56 | $4,275 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,756 | $172 |
| New patient visit (45+ min) | 23 | $2,561 | $111 |
Medicaid work
$6,054 in 2024
Medicaid paid $6,054 for 41 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 41 | $6,054 |
| 2024 | 41 | 1 | 16 | $6,054 |
| 2023 | 136 | 3 | 15 | $8,510 |
| 2022 | 15 | 1 | 15 | $72 |
| 2021 | 59 | 2 | 15 | $5,970 |
| 2019 | 114 | 4 | 21 | $1,358 |
| 2018 | 51 | 3 | 14 | $336 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 69 | $8,102 |
| Diffusing capacity | 54 | $277 |
| EVALUATION OF WHEEZING | 13 | $132 |
2022
| Diffusing capacity | 15 | $72 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 46 | $5,076 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $895 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $673 |
| EVALUATION OF WHEEZING | 34 | $423 |
| Diffusing capacity | 35 | $174 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 14 | $88 |
2018
| EVALUATION OF WHEEZING | 13 | $158 |
| Diffusing capacity | 26 | $113 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 12 | $66 |
Drugs they prescribed that Part D paid
$39,874
Pharmacies billed $39,874 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 202) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
112 generic and 90 brand-name prescriptions · $39,874 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 24 | $19,872 | $828 |
| Fluticasone-Salmeterol | 29 | $1,853 | $64 |
| Albuterol Sulfate Hfa | 27 | $594 | $22 |
| Montelukast | 15 | $202 | $13 |
| Fluticasone Propionate | 20 | $199 | $10 |
See all 6 drugs
| Trelegy Ellipta | 24 | $19,872 | $828 |
| Fluticasone-Salmeterol | 29 | $1,853 | $64 |
| Albuterol Sulfate Hfa | 27 | $594 | $22 |
| Montelukast | 15 | $202 | $13 |
| Fluticasone Propionate | 20 | $199 | $10 |
| Gabapentin | 11 | $94 | $9 |
Year by year
| 2024 | 202 | 40 | 0% (0) | 45% | $39,874 |
| 2023 | 210 | 50 | 0% (0) | 61% | $61,305 |
| 2022 | 200 | 39 | 0% (0) | 63% | $104,724 |
| 2021 | 162 | 33 | 0% (0) | 62% | $62,014 |
| 2020 | 215 | 44 | 0% (0) | 68% | $91,306 |
| 2019 | 368 | 78 | 0% (0) | 65% | $173,669 |
| 2018 | 462 | 93 | 0% (0) | 56% | $168,355 |
| 2017 | 435 | 80 | None | 50% | $125,400 |
| 2016 | 363 | 67 | None | 53% | $126,577 |
| 2015 | 302 | 63 | 0% (0) | 50% | $82,006 |
| 2014 | 323 | 61 | None | 52% | $63,116 |
| 2013 | 318 | 64 | None | 50% | $51,473 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Trelegy Ellipta | 29 | $22,733 | $784 |
| Anoro Ellipta | 14 | $6,547 | $468 |
| Symbicort | 12 | $4,732 | $394 |
| Wixela Inhub | 11 | $3,185 | $290 |
| Fluticasone-Salmeterol | 22 | $2,628 | $119 |
| Albuterol Sulfate Hfa | 24 | $987 | $41 |
| Fluticasone Propionate | 20 | $397 | $20 |
2022: 7 drugs
| Trelegy Ellipta | 22 | $19,083 | $867 |
| Advair Diskus | 19 | $14,110 | $743 |
| Anoro Ellipta | 20 | $8,925 | $446 |
| Wixela Inhub | 21 | $5,126 | $244 |
| Fluticasone-Salmeterol | 12 | $1,917 | $160 |
| Albuterol Sulfate Hfa | 29 | $1,391 | $48 |
| Fluticasone Propionate | 12 | $197 | $16 |
2021: 5 drugs
| Trelegy Ellipta | 29 | $23,920 | $825 |
| Anoro Ellipta | 16 | $10,056 | $629 |
| Wixela Inhub | 19 | $5,801 | $305 |
| Albuterol Sulfate Hfa | 22 | $963 | $44 |
| Fluticasone Propionate | 11 | $124 | $11 |
2020: 8 drugs
| Advair Diskus | 17 | $14,322 | $842 |
| Trelegy Ellipta | 20 | $12,570 | $629 |
| Symbicort | 25 | $12,348 | $494 |
| Spiriva | 12 | $11,031 | $919 |
| Anoro Ellipta | 15 | $9,241 | $616 |
| Wixela Inhub | 18 | $6,264 | $348 |
| Ventolin Hfa | 18 | $1,654 | $92 |
| Fluticasone Propionate | 15 | $393 | $26 |
2019: 9 drugs
| Spiriva | 48 | $32,935 | $686 |
| Symbicort | 48 | $21,303 | $444 |
| Advair Diskus | 23 | $16,866 | $733 |
| Breo Ellipta | 15 | $5,383 | $359 |
| Wixela Inhub | 12 | $4,127 | $344 |
| Ventolin Hfa | 23 | $1,429 | $62 |
| Azithromycin | 18 | $548 | $30 |
| Fluticasone Propionate | 18 | $466 | $26 |
| Prednisone | 12 | $62 | $5 |
2018: 13 drugs
| Spiriva | 77 | $43,260 | $562 |
| Advair Diskus | 37 | $27,190 | $735 |
| Symbicort | 18 | $7,643 | $425 |
| Incruse Ellipta | 13 | $7,589 | $584 |
| Breo Ellipta | 13 | $6,103 | $469 |
| Ventolin Hfa | 40 | $2,497 | $62 |
| Proair Hfa | 12 | $734 | $61 |
| Montelukast | 30 | $733 | $24 |
| Azithromycin | 27 | $733 | $27 |
| Fluticasone Propionate | 35 | $583 | $17 |
| Levofloxacin | 15 | $246 | $16 |
| Prednisone | 21 | $152 | $7 |
| Omeprazole | 11 | $44 | $4 |
2017: 13 drugs
| Spiriva | 75 | $32,302 | $431 |
| Advair Diskus | 24 | $17,358 | $723 |
| Symbicort | 20 | $6,627 | $331 |
| Ventolin Hfa | 32 | $1,714 | $54 |
| Proair Hfa | 16 | $1,578 | $99 |
| Ethambutol | 20 | $1,368 | $68 |
| Rifampin | 20 | $1,126 | $56 |
| Montelukast | 42 | $706 | $17 |
| Azithromycin | 11 | $467 | $42 |
| Fluticasone Propionate | 33 | $391 | $12 |
| Prednisone | 23 | $227 | $10 |
| Omeprazole | 16 | $151 | $9 |
| Levofloxacin | 12 | $97 | $8 |
2016: 8 drugs
| Spiriva | 66 | $25,396 | $385 |
| Advair Diskus | 37 | $24,068 | $650 |
| Symbicort | 21 | $8,138 | $388 |
| Proair Hfa | 27 | $2,383 | $88 |
| Montelukast | 27 | $425 | $16 |
| Prednisone | 40 | $326 | $8 |
| Fluticasone Propionate | 15 | $241 | $16 |
| Omeprazole | 11 | $102 | $9 |
2015: 8 drugs
| Advair Diskus | 41 | $17,007 | $415 |
| Spiriva | 40 | $12,558 | $314 |
| Symbicort | 13 | $3,468 | $267 |
| Proair Hfa | 21 | $1,577 | $75 |
| Azithromycin | 23 | $1,082 | $47 |
| Montelukast | 24 | $881 | $37 |
| Fluticasone Propionate | 37 | $512 | $14 |
| Prednisone | 18 | $137 | $8 |
2014: 9 drugs
| Advair Diskus | 37 | $14,960 | $404 |
| Spiriva | 39 | $12,649 | $324 |
| Symbicort | 34 | $10,294 | $303 |
| Montelukast | 27 | $2,205 | $82 |
| Nasonex | 13 | $2,149 | $165 |
| Azithromycin | 22 | $1,160 | $53 |
| Proair Hfa | 12 | $578 | $48 |
| Fluticasone Propionate | 27 | $523 | $19 |
| Prednisone | 23 | $273 | $12 |
2013: 9 drugs
| Advair Diskus | 56 | $21,721 | $388 |
| Spiriva | 24 | $8,337 | $347 |
| Azithromycin | 29 | $1,730 | $60 |
| Nasonex | 11 | $1,567 | $142 |
| Proventil Hfa | 16 | $1,548 | $97 |
| Proair Hfa | 19 | $1,109 | $58 |
| Fluticasone Propionate | 42 | $1,058 | $25 |
| Montelukast | 19 | $984 | $52 |
| Prednisone | 18 | $106 | $6 |
Money from drug and device companies
$1,600 in 2021
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | Ofev | $1,600 | 1 payment
|
See the published payment
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2021-05-27 | Ofev | $1,600 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1033251152
- Licence
- CA A87822California A87822: Current · expires 2028-04-30
- Trained
- University of Minnesota Medical School, 1998
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A878220
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-13
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.